A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia

Blood Adv. 2020 Feb 11;4(3):445-448. doi: 10.1182/bloodadvances.2019001182.

Abstract

  1. Targeted RNA sequencing detected a cryptic G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia and normal FISH studies.

  2. Consistent with the patient’s response to imatinib, we demonstrate this rearrangement is oncogenic and sensitive to TKI in cell culture.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • DNA Helicases
  • Eosinophilia* / drug therapy
  • Eosinophilia* / genetics
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Neoplasms*
  • Poly-ADP-Ribose Binding Proteins
  • RNA Helicases
  • RNA Recognition Motif Proteins
  • Receptor, Platelet-Derived Growth Factor beta / genetics

Substances

  • Poly-ADP-Ribose Binding Proteins
  • RNA Recognition Motif Proteins
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor beta
  • DNA Helicases
  • RNA Helicases